Validation of the 12-gene colon cancer recurrence score (RS) in NSABP C07 as a predictor of recurrence in stage II and III colon cancer patients treated with 5FU/LV (FU) and 5FU/LV+oxaliplatin (FU plus Ox).

被引：0
|
作者：
O'Connell, Michael
Lee, Mark
Lopatin, Margarita
Yothers, Greg
Clark-Langone, Kim
Millward, Carl
Paik, Soonmyung
Sharif, Saima
Shak, Steven
Wolmark, Norman
机构：
[1] Natl Surg Adjuvant Breast & Bowel Project, Pittsburgh, PA USA
[2] Genom Hlth, Redwood City, CA USA
[3] NSABP Biostat Ctr, Pittsburgh, PA USA
[4] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA
[5] Allegheny Gen Hosp, Pittsburgh, PA 15212 USA
[6] Allegheny Gen Hosp, Allegheny Canc Ctr, Pittsburgh, PA 15212 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3512
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase II trial of 5-fluorouracil (5FU)/leucovorin (LV), irinotecan, and oxaliplatin (FOLFOXIRI) plus cetuximab in patients with metastatic colorectal cancer (mCRC).
    Sougklakos, I.
    Vardakis, N. K.
    Kampouraki, E.
    Kotortsi, I.
    Androulakis, N. E. M.
    Vamvakas, L.
    Kalbakis, K.
    Hatzidaki, D.
    Mavroudis, D.
    Georgoulias, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [22] Cost-effectiveness analysis of oxaliplatin/5-FU/LV in adjuvant treatment of stage III colon cancer in the US
    Aballea, S
    Chancellor, J
    Raikou, M
    Drummond, M
    Weinstein, M
    Jourdan, S
    Carita, P
    Bridgewater, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 254S - 254S
  • [23] Cost-effectiveness analysis of oxaliplatin/5-FU/LV in adjuvant treatment of stage III colon cancer in the UK
    Aballea, S.
    Chancellor, J. V. M.
    Raikou, M.
    Drummond, M. F.
    Jourdan, S.
    Carita, P.
    Bridgewater, J.
    Boler, A.
    EJC SUPPLEMENTS, 2005, 3 (02): : 178 - 178
  • [24] Cost-effectiveness analysis of oxaliplatin/5-FU/LV in adjuvant treatment of stage III colon cancer in Germany
    Aballea, S.
    Frick, M.
    Diel, R.
    Rosenfeld, S.
    Huppertz, E.
    Sievert, M.
    Jourdan, S.
    Drummond, M.
    Weinstein, M. C.
    Reichardt, P.
    EJC SUPPLEMENTS, 2005, 3 (02): : 182 - 183
  • [25] Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III
    Taal, BG
    Van Tinteren, H
    Zoetmulder, F
    BRITISH JOURNAL OF CANCER, 2001, 85 (10) : 1437 - 1443
  • [26] Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III
    B G Taal
    H Van Tinteren
    F A N Zoetmulder
    British Journal of Cancer, 2001, 85 : 1437 - 1443
  • [27] Validation of the 12-gene colon cancer recurrence score® assay as a predictor of recurrence risk in stage II and III rectal cancer patients
    Reimers, M. S.
    Kuppen, P. J. K.
    Lee, M.
    Tezcan, H.
    Putter, H.
    Lopatin, M.
    Clark-Langone, K.
    Liefers, G. J.
    Shak, S.
    van de Velde, C. J. H.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S2 - S2
  • [28] Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5FU-LV and irinotecan (PETACC 3-EORTC 40993-SAKK 60/00 trial)
    Tejpar, S.
    Bosman, F.
    Delorenzi, M.
    Fiocca, R.
    Yan, P.
    Klingbiel, D.
    Dietrich, D.
    Van Cutsem, E.
    Labianca, R.
    Roth, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [29] Validation of the 12-Gene Colon Cancer Recurrence Score as a Predictor of Recurrence Risk in Stage II and II Rectal Cancer Patients
    Reimers, Marlies S.
    Kuppen, Peter J. K.
    Lee, Mark
    Lopatin, Margarita
    Tezcan, Haluk
    Putter, Hein
    Clark-Langone, Kim
    Liefers, Gerrit Jan
    Shak, Steve
    van de Velde, Cornelis J. H.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (11):
  • [30] A phase I study of bortezomib in combination with 5FU/LV plus oxaliplatin in patients (pts) with advanced colorectal cancer (CRC): EORTC 16029
    Lacombe, D. A.
    Caponigro, F.
    Anthoney, A.
    Bauer, J.
    Govaerts, A.
    Milano, A.
    Marreaud, S.
    Twelves, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345